Vemurafenib
- Generic Name
- Vemurafenib
- Brand Names
- Zelboraf
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18ClF2N3O3S
- CAS Number
- 918504-65-1
- Unique Ingredient Identifier
- 207SMY3FQT
- Background
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...
- Indication
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...
- Associated Conditions
- Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
- Associated Therapies
- -
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Fondazione Melanoma Onlus
- Target Recruit Count
- 11
- Registration Number
- NCT01959633
- Locations
- 🇮🇹
Fondazione G.Pascale, Napoli, Italy
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 7
- Registration Number
- NCT01943422
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Philip Friedlander
- Target Recruit Count
- 3
- Registration Number
- NCT01942993
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT01910181
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Sun Yet-sen University Cancer Center, Guangzhou, China
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 922
- Registration Number
- NCT01909453
- Locations
- 🇺🇸
Tulsa Cancer Institute PLLC, Tulsa, Oklahoma, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Tennessee Medical Center Cancer Institute, Knoxville, Tennessee, United States
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01851824
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
- Conditions
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01849666
Radiation Use During Vemurafenib Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01843738
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01844674
- Locations
- 🇨🇾
Bank of Cyprus Oncology Center, Nicosia, Cyprus
🇨🇦CSSS champlain - Charles-Le Moyne, Greenfield Park, Quebec, Canada
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.